Show simple item record

dc.contributor.authorDe Marco Verissimo, Carolina
dc.contributor.authorO'Brien, Carol
dc.contributor.authorLópez Corrales, Jesús
dc.contributor.authorDorey, Amber
dc.contributor.authorCwiklinski, Krystyna
dc.contributor.authorLalor, Richard
dc.contributor.authorDoyle, Jack M.
dc.contributor.authorField, Stephen
dc.contributor.authorMasterson, Claire
dc.contributor.authorRibes Martinez, Eduardo
dc.contributor.authorHughes, Gerry
dc.contributor.authorBergin, Colm
dc.contributor.authorWalshe, Kieran
dc.contributor.authorMcNicholas, Bairbre
dc.contributor.authorLaffey, John G.
dc.contributor.authorDalton, John P.
dc.contributor.authorKerr, Colm
dc.contributor.authorDoyle, Sean
dc.identifier.citationDe Marco Verissimo, Carolina, O'Brien, Carol, López Corrales, Jesús, Dorey, Amber, Cwiklinski, Krystyna, Lalor, Richard, Doyle, Jack M., Field, Stephen, Masterson, Claire, Ribes Martinez, Eduardo, Hughes, Gerry, Bergin, Colm, Walshe, Kieran, McNicholas, Bairbre, Laffey, John G., Dalton, John P., Kerr, Colm, Doyle, Sean. (2021). Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. Epidemiology and Infection, 149, e140. doi: 10.1017/S0950268821001308en_IE
dc.description.abstractThe novel coronavirus, severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is the causative agent of the 2020 worldwide coronavirus pandemic. Antibody testing is useful for diagnosing historic infections of a disease in a population. These tests are also a helpful epidemiological tool for predicting how the virus spreads in a community, relating antibody levels to immunity and for assessing herd immunity. In the present study, SARS-CoV-2 viral proteins were recombinantly produced and used to analyse serum from individuals previously exposed, or not, to SARS-CoV-2. The nucleocapsid (Npro) and spike subunit 2 (S2Frag) proteins were identified as highly immunogenic, although responses to the former were generally greater. These two proteins were used to develop two quantitative enzyme-linked immunosorbent assays (ELISAs) that when used in combination resulted in a highly reliable diagnostic test. Npro and S2Frag-ELISAs could detect at least 10% more true positive coronavirus disease-2019 (COVID-19) cases than the commercially available ARCHITECT test (Abbott). Moreover, our quantitative ELISAs also show that specific antibodies to SARS-CoV-2 proteins tend to wane rapidly even in patients who had developed severe disease. As antibody tests complement COVID-19 diagnosis and determine population-level surveillance during this pandemic, the alternative diagnostic we present in this study could play a role in controlling the spread of the virus.en_IE
dc.description.sponsorshipThis work was supported by the Science Foundation Ireland (SFI) COVID-19 Rapid Response Funding Call, proposal ID 20/COV/0023 and 20/COV/0048. Mass spectrometry facilities were funded by a Science Foundation Ireland infrastructure award to SD (12/RI/2346(3)).en_IE
dc.publisherCambridge University Pressen_IE
dc.relation.ispartofEpidemiology And Infectionen
dc.rightsAttribution 4.0 International (CC BY 4.0)
dc.subjectnucleocapsid proteinen_IE
dc.subjectspike proteinen_IE
dc.titleImproved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA testsen_IE
dc.contributor.funderScience Foundation Irelanden_IE
dc.local.contactJesús Lopez. Email:
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Research Infrastructure Programme/12/RI/2346 (3)/IE/Thermo Scientific Q Exactive benchtop LC-MS/MS mass spectrometer/en_IE

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)